Melatonin and Sleep Disturbances in Alzheimer's Disease

Area of Science:

• Neuroscience
• Gerontology
• Pharmacology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing cognitive and sleep decline.
• Sleep disturbances (SD) exacerbate AD symptoms and are linked to disease pathophysiology.
• Reduced melatonin levels, crucial for sleep regulation and neuroprotection, are observed even in early AD stages.

Purpose of the Study:

• To review the efficacy of exogenous melatonin in treating sleep disturbances (SD) in Alzheimer's disease (AD).
• To explore the potential mechanisms by which melatonin may alleviate AD neuropathology and SD.
• To identify factors contributing to discrepancies in study results regarding melatonin's effectiveness.

Main Methods:

• Systematic review of existing studies on exogenous melatonin for SD in AD.
• Analysis of factors influencing melatonin efficacy, including dosage, timing, and duration.
• Consideration of comorbid conditions, genetics, and environmental influences.

Main Results:

• Most studies suggest melatonin can ameliorate SD in AD patients.
• Some studies report conflicting results, indicating variability in melatonin's effectiveness.
• Discrepancies may stem from differences in administration protocols, disease severity, and individual patient factors.

Conclusions:

• Exogenous melatonin shows promise for managing SD in AD, but results are inconsistent.
• Further extensive clinical trials with varied dosages, longer durations, and combination therapies (e.g., bright light, melatonin agonists) are warranted.
• Clarifying optimal melatonin treatment strategies is crucial for improving patient outcomes in AD.